JOP20220204A1 - الأجسام المضادة لـ cd19 البشرية - Google Patents
الأجسام المضادة لـ cd19 البشريةInfo
- Publication number
- JOP20220204A1 JOP20220204A1 JOP/2022/0204A JOP20220204A JOP20220204A1 JO P20220204 A1 JOP20220204 A1 JO P20220204A1 JO P20220204 A JOP20220204 A JO P20220204A JO P20220204 A1 JOP20220204 A1 JO P20220204A1
- Authority
- JO
- Jordan
- Prior art keywords
- antibodies
- human
- compositions
- present disclosure
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
يتعلق الكشف الحالي بالأجسام المضادة التي تربط CD19 البشري ("الأجسام المضادة لـ CD19 البشرية" أو "الأجسام المضادة لـ CD19 البشرية")، تركيبات تتضمن هذه الأجسام المضادة لـ CD19 البشرية، وطرق استخدام هذه الأجسام المضادة لـ CD19 البشرية.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062983093P | 2020-02-28 | 2020-02-28 | |
PCT/US2021/018989 WO2021173471A1 (en) | 2020-02-28 | 2021-02-22 | Anti-human cd19 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20220204A1 true JOP20220204A1 (ar) | 2023-01-30 |
Family
ID=74885029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2022/0204A JOP20220204A1 (ar) | 2020-02-28 | 2021-02-22 | الأجسام المضادة لـ cd19 البشرية |
Country Status (20)
Country | Link |
---|---|
US (1) | US11623956B2 (ar) |
EP (1) | EP4110815A1 (ar) |
JP (1) | JP7450743B2 (ar) |
KR (1) | KR20220132579A (ar) |
CN (1) | CN115151570A (ar) |
AR (1) | AR121370A1 (ar) |
AU (1) | AU2021225792A1 (ar) |
BR (1) | BR112022015902A2 (ar) |
CA (1) | CA3169155A1 (ar) |
CL (1) | CL2022002329A1 (ar) |
CO (1) | CO2022012212A2 (ar) |
CR (1) | CR20220421A (ar) |
DO (1) | DOP2022000173A (ar) |
EC (1) | ECSP22067275A (ar) |
IL (1) | IL295494A (ar) |
JO (1) | JOP20220204A1 (ar) |
MX (1) | MX2022010621A (ar) |
PE (1) | PE20221593A1 (ar) |
TW (1) | TWI790548B (ar) |
WO (1) | WO2021173471A1 (ar) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202346576A (zh) | 2022-04-13 | 2023-12-01 | 新加坡商泰莎治療有限公司 | 治療性t細胞產品 |
TW202346359A (zh) | 2022-04-15 | 2023-12-01 | 美商凱維那醫療公司 | 用於治療自體免疫疾病之方法及組合物 |
WO2023240064A1 (en) | 2022-06-08 | 2023-12-14 | Kyverna Therapeutics, Inc. | Methods and compositions for treating autoimmune disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1966245E (pt) | 2005-12-30 | 2011-08-31 | Merck Patent Gmbh | Anticorpos anti-cd19 com imunogenicidade reduzida |
PL2066349T3 (pl) * | 2006-09-08 | 2012-09-28 | Medimmune Llc | Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych |
WO2015171863A1 (en) | 2014-05-08 | 2015-11-12 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | USING B-CELL-TARGETING ANTIGEN IgG FUSION AS TOLEROGENIC PROTEIN THERAPY FOR TREATING ADVERSE IMMUNE RESPONSES |
ES2963807T3 (es) | 2016-06-08 | 2024-04-02 | Xencor Inc | Tratamiento de enfermedades relacionadas con la IgG4 con anticuerpos anti-CD19 de reticulación a CD32B |
-
2021
- 2021-02-18 AR ARP210100425A patent/AR121370A1/es unknown
- 2021-02-18 TW TW110105560A patent/TWI790548B/zh active
- 2021-02-22 CA CA3169155A patent/CA3169155A1/en active Pending
- 2021-02-22 WO PCT/US2021/018989 patent/WO2021173471A1/en active Application Filing
- 2021-02-22 CR CR20220421A patent/CR20220421A/es unknown
- 2021-02-22 PE PE2022001851A patent/PE20221593A1/es unknown
- 2021-02-22 JP JP2022551767A patent/JP7450743B2/ja active Active
- 2021-02-22 KR KR1020227029214A patent/KR20220132579A/ko active Search and Examination
- 2021-02-22 BR BR112022015902A patent/BR112022015902A2/pt unknown
- 2021-02-22 IL IL295494A patent/IL295494A/en unknown
- 2021-02-22 AU AU2021225792A patent/AU2021225792A1/en active Pending
- 2021-02-22 MX MX2022010621A patent/MX2022010621A/es unknown
- 2021-02-22 EP EP21712613.5A patent/EP4110815A1/en active Pending
- 2021-02-22 CN CN202180016785.XA patent/CN115151570A/zh active Pending
- 2021-02-22 JO JOP/2022/0204A patent/JOP20220204A1/ar unknown
- 2021-02-22 US US17/181,184 patent/US11623956B2/en active Active
-
2022
- 2022-08-25 CL CL2022002329A patent/CL2022002329A1/es unknown
- 2022-08-26 CO CONC2022/0012212A patent/CO2022012212A2/es unknown
- 2022-08-26 EC ECSENADI202267275A patent/ECSP22067275A/es unknown
- 2022-08-26 DO DO2022000173A patent/DOP2022000173A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP4110815A1 (en) | 2023-01-04 |
CR20220421A (es) | 2022-09-23 |
IL295494A (en) | 2022-10-01 |
CN115151570A (zh) | 2022-10-04 |
JP7450743B2 (ja) | 2024-03-15 |
AR121370A1 (es) | 2022-06-01 |
DOP2022000173A (es) | 2022-10-31 |
MX2022010621A (es) | 2022-11-30 |
CL2022002329A1 (es) | 2023-04-10 |
CO2022012212A2 (es) | 2022-09-09 |
ECSP22067275A (es) | 2022-09-30 |
KR20220132579A (ko) | 2022-09-30 |
US20210269520A1 (en) | 2021-09-02 |
JP2023515219A (ja) | 2023-04-12 |
CA3169155A1 (en) | 2021-09-02 |
WO2021173471A1 (en) | 2021-09-02 |
BR112022015902A2 (pt) | 2022-10-04 |
PE20221593A1 (es) | 2022-10-10 |
US11623956B2 (en) | 2023-04-11 |
AU2021225792A1 (en) | 2022-09-15 |
TWI790548B (zh) | 2023-01-21 |
TW202146451A (zh) | 2021-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202211057B (en) | Anti-trem2 antibodies and methods of use thereof | |
PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
JOP20220204A1 (ar) | الأجسام المضادة لـ cd19 البشرية | |
PH12021550690A1 (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
CR20190486A (es) | Anti-cd33 antibodies and methods of use thereof | |
CR20210057A (es) | Anticuerpos anti-sortilina y métodos para su uso | |
MX2020013324A (es) | Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos. | |
MX2022007231A (es) | Anticuerpos anti-mertk y metodos de uso de los mismos. | |
MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
MX2022001260A (es) | Anticuerpos anti-ms4a4a y metodos de uso de los mismos. | |
MX2021000933A (es) | Anticuerpos anti-siglec-5 y métodos para su uso. | |
MX2022001449A (es) | Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos. | |
MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
EA202092508A1 (ru) | Составы на основе антител к pd-l1 человека | |
MX2021007589A (es) | Anticuerpos anti il-36 y procedimientos de uso de estos. | |
MX2020013172A (es) | Anticuerpos anti-siglec-7 y sus metodos de uso. | |
MX2021000280A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2021000287A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2023014154A (es) | Anticuerpos anti-ccr8. | |
ZA202205813B (en) | Trpv1 epitopes and antibodies | |
CR20240046A (es) | Anticuerpos contra el receptor alfa de la interleucina-4 humana | |
MX2023012325A (es) | Anticuerpos anti-tslp modificados. |